Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.

You may also be interested in...



At PharmAsia Summit, VCs Discuss Financing Innovation in Asia

SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs

At PharmAsia Summit, VCs Discuss Financing Innovation in Asia

SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs

Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM

TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma

Related Content

UsernamePublicRestriction

Register

PL032870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel